Not yet recruitingPhase 1

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Eloralintide on Insulin Sensitivity and Metabolism in Adult Participants With Overweight or Obesity

Lead sponsor

Eli Lilly and Company

Asset

Eloralintide

Subcutaneous · Amylin analog

Listed sites

Recruiting sites

Estimated enrollment

115

Study population

Obesity / overweight

Eligibility highlights

•BMI 25-45•HbA1c ≤6.5%

Primary endpoint

•Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07665879

Org study ID27756

Secondary ID2025-523873-41-00

Secondary IDJ3R-MC-YDAKEli Lilly and Company

Timeline

Milestones

Study first posted2026-06-24actual

Last update posted2026-06-24actual

Study start2026-06estimated (month precision)

Primary completion2027-08estimated (month precision)

Study completion2027-08estimated (month precision)

Assets

Investigational agents

Eloralintide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Have an hemoglobin A1c (HbA1c) value at screening of less than 6.5 percent (%).

•Have a body mass index between 25 and 45 Kilogram per Square Meter (kg/m²).

•Have had a stable body weight that has changed by less than 5% during the 3 months prior to screening.

•Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB). Individuals of childbearing potential (IOCBP) and individuals not of childbearing potential (INOCBP) may participate in this study.

Exclusion criteria

•Have type 1 or type 2 diabetes mellitus, a history of ketoacidosis, or of hyperosmolar state or coma. Note: Participants with a history of gestational diabetes are eligible to participate in this study.

•Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis.

•Have a known clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal (GI) motility to a significant extent.

•Have a prior or planned surgical treatment for obesity. Exceptions: The following are allowed if they occurred more than 1 year before screening:

-liposuction

-cryolipolysis, or

-abdominoplasty.

•Are unwilling to comply with the lifestyle and dietary restrictions required for this study.

•Are individuals AFAB who are lactating.

•Are individuals AFAB who are pregnant or intend to become pregnant or to breastfeed during the study, or individuals AMAB who intend to conceive a pregnancy during the study.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Change From Baseline In Body Weight

Time frame:Baseline, Week 24

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

Change From Baseline In Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin Sensitivity (M-value)

Time frame:Baseline, Week 24

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.